No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

Aluminum-adsorbed vaccines do not increase risk for autoimmune disorder, atopic or allergic disorder, or neurodevelopmental disorder.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Respiratory symptom patterns and their triggers may reflect pathophysiological mechanisms of distinct subtypes of childhood wheezing disorders.

Patients with bronchiectasis from different European countries have strikingly different variations in microbiome composition and resistome.

After a patient loses her leg due to medical errors, a pulmonologist is held liable for not acting quickly to address another ...

The FDA has granted marketing authorization to JUUL Labs, allowing the sale of the JUUL System, a closed, cartridge-based nicotine vapor product, in the US.

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

The prevalence of long COVID-typical symptom clusters was relatively high among a cohort of adults 2 years after initial COVID-19 infection.

Reductions in chronic rhinosinusitis symptom severity from 2017 to 2023 are due to clinical practice and not anatomical variation.

An increased risk for comorbid insomnia and sleep apnea (COMISA) is significantly associated with reduced work ability.

Children with hematologic malignancies continue to exhibit increased IPD risk despite an overall decline in pediatric IPD after the introduction of the PCV13 vaccine.